Perfusion Tech ApS: Financial statements 2019
CVR: 38238213
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -538,894 and a net result of DKK -596,373 compared with DKK -238,245 the year before. Equity in the 2019 report amounted to DKK -329,031. The company had 1 employee in the financial year.
- Gross Profit
- DKK -538,894
- Profit/Loss
- DKK -596,373
- Equity
- DKK -329,031
- Total Assets
- DKK 621,530
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -539 t. | -596 t. | -329 t. | 1 |
| 2018 | - | -262 t. | -238 t. | -453 t. | - |
| 2017 | - | -278 t. | -272 t. | -214 t. | - |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 14, 2019, EY Godkendt Revisionspartnerselskab has been appointed auditor of Perfusion Tech ApS.
As of November 14, 2019, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Perfusion Tech ApS.
Perfusion Tech ApS has published its annual report for 2018. Gross profit came to DKK -261,728, and the net result was DKK -238,245.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The board consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. According to the 2025 annual report, the company had an average of 11 employees. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity in the 2025 report amounted to DKK -9,640,655.